

TRANSMITTAL LETTER

Application Number : 10/562,107
Filing Date : 22 Dec 2005
First Named Inventor : Wai Ming WONG
Art Unit : 1646
Examiner Name : RUSSEL, Jeffrey E
Attorney Docket Number : P001.004.NPEUS

30 Jan 2008
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir,

In response to the Notice of Non-Compliant Amendment, which was mailed by the Office on January 9, 2008, the Applicant hereby presents the following:


1. Corrections to the Amendments to the Claims [Pages 2-4].

The Applicant declares that the corrections made herewith do not introduce any new matter.

Furthermore, the Applicant noted that the substitute specification filed July 12, 2007 has not been entered and kindly requests said amended specification to be withdrawn from the Office's consideration.

The Commissioner is hereby authorized to charge any additional fees which may be required, now or in the future, or credit any overpayment, to Deposit Account No. 503695.

Yours sincerely,



Jacqueline Lui
Registration No. 44,214
Customer No. 56374
EAGLE IP LIMITED

22/F Kwai Hung Holdings Centre, 89 King's Road, North Point, Hong Kong
Tel : (866) 624-4715 Fax : (212) 419-2303 email : eip@eip.hk

<00023622-KC>

Corrections to the Amendments to the Claims:

The corrected listing of claims presented below is based on the claims numbering 1-29 filed originally in the PCT International application, incorporating the preliminary amendments to the claims filed December 22, 2005 and October 31, 2005, and will replace all prior versions, and listings, of amendments made to the claims in the application:

Listing of Claims:

1. (canceled)
2. (canceled)
3. (currently amended) An isolated, or purified peptide ~~according to claim 1~~ consisting essentially of a the tripeptide of amino acid sequence L-Tyrosyl-L-Seryl-L-Valine.
- 4.. (canceled)
5. (canceled)
6. (canceled)
7. (canceled)
8. (currently amended) A pharmaceutical composition, ~~according to Claim 7~~ comprising an isolated, purified tripeptide of amino acid sequence the tripeptide L-Tyrosyl-L-Seryl-L-Valine.
9. (canceled)
10. (canceled)
11. (canceled)
12. (canceled)
13. (canceled)
14. (currently amended) A method of reducing, countering or inhibiting T-lymphocyte transformation or cell proliferation, or a disease or condition associated with it, comprising administering to a subject in need of treatment a therapeutically effective amount of a tripeptide of amino acid sequence the effects of a human disease comprising administering a pharmaceutically effective

~~dose of a polypeptide consisting of the tripeptide L-Tyrosyl-L-Seryl-L-Valine to a human.~~

15. (canceled)

16. (currently amended) The method of Claim ~~14~~ 45, wherein the disease or condition is associated with, or comprises a said cell proliferative disorder is cancer.

17. (currently amended) The method of Claim ~~14~~ 46, wherein the disease or condition is associated with, or comprises ~~said cancer is selected from the group consisting of~~ liver cancer, leukemia, lung cancer, melanoma or ~~and~~ cervical cancer.

18. (canceled)

19. (canceled)

20. (canceled)

21. (canceled)

22. (canceled)

23. (canceled)

24. (canceled)

25. (canceled)

26. (canceled)

27. (canceled)

28. (canceled)

29. (canceled)

30. (new) The peptide of Claim 3, which comprises a substantially pure tripeptide.

31. (new) The method of Claim 14, wherein the therapeutically effective amount of the tripeptide comprises an anti-T-cell transformation, anti-cell proliferation, or anti-cancer effective amount of the tripeptide.

32. (new) The method of Claim 14, wherein the therapeutically effective amount of the tripeptide comprises a liver cancer, leukemia cell, cervical cancer, lung cancer or melanoma growth countering, reducing or inhibiting amount of the tripeptide.

33. (new) The method of Claim 14, wherein the tripeptide is administered as a pharmaceutical composition further comprising a pharmaceutically or biologically acceptable carrier.